drugset / Trial / NCT00626743

Phase I Study to Investigate the Effect on the Blood Pressure After Oral Administration of SK3530 and Amlodipine

NCT00626743

Phase 1 Completed 13 enrolled SK Chemicals Co., Ltd.
RandomizedCrossoverQuadruple-blindTreatment

Summary

To assess the pharmacodynamic effects of co-administrated SK3530 (PDE5 inhibitor) and Amlodipine, phase I study in Hypertensive patient was designed.

Timeline

Start
2008-05
Primary completion
2009-05
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirodenafil Small molecule 100 mg Oral
Background Amlodipine Other / unclassified Oral

Indications